Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteoarthritis Hand Osteoarthritis Finger Age ≥18 years. 2. Hand OA according to the ACR above. 3. Hand OA finger pain: Pain at rest ≥40 mm on VAS (0 to 100 mm range)  Comorbidities 1. Other known medical disease that may affect joints, e.g. RA, gout, PsA 2. Positive anti-cyclic citrullinated peptide (>10 kU/L) 3. Known cutaneous deposition diseases (e.g. amyloidosis or porphyria). 4. Known blood dyscrasias and coagulation disorders 5. Known malignancy (except successfully treated squamous or basal cell skin carcinoma) 6. Elevated alanine transaminase (>45 U/L females, >70 U/L for males) 7. Creatinine clearance ≤60 ml/min 8. Elevated creatine kinase (>210 U/L females, >280 U/L for males) 9. Known allergies towards the interventions 10. Drug or alcohol abuse in the last year 11. Generalised pain syndromes such as fibromyalgia 12. Current reflux 13. Current or recurrent diarrhoeal illnesses 14. Current abdominal pain 15. Known peripheral neuropathies 16. Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as e.g. psychiatric disorders. Medical history 17. History of hand surgery within 12 months prior enrolment. 18. History of arthroplasty or arthrodesis in the hand Management strategies 19. Treatment with P-glycoprotein inhibitors and/or cytochrome P450 3A4 (CYP3A4) inhibitors, see section "Colchicine safety in drug-drug interactions" and table 7. If potential participants have been treated with these pharmaceuticals previously, treatment must be terminated 5 half-lifes before initiation of study drug. 20. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3 months. 21. Participation in experimental device or experimental drug study 3 months prior to enrolment. 22. Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before 23. Intra-articular corticosteroids into any joint 1 months before 24. Current use of synthetic or non-synthetic opioids 25. Scheduled surgery during study participation 26. Planning to start other treatment for hand OA in the study participation period. Reproductive system 27. Pregnancy. 28. Planned pregnancy within the study period, 3 months after end of study treatment for female fertile participant and 6 months after end of study treatment for male participant. 29. Insufficient anti-conception therapy for female fertile participants within the study period and 3 months after end of study treatment. Sufficient anti-conception therapy consists of intra-uterine device (coil),hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual abstinence Female participants are considered infertile if they are postmenopausal or if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy or bilateral oophorectomy). Postmenopausal state is defined as no menses for 12 months without alternative medical cause before in the study. Menopause state will be confirmed by measurement of follicle stimulating hormone. 30. Insufficient anti-conception therapy for male participants within the study period and 6 months after end of study treatment. Sufficient anti-conception therapy consists of condom or sexual abstinence. Male participants are considered sterile if they have undergone surgical sterilisation (vasectomy). 31. Breast-feeding A target hand will be selected for outcome assessment once individual fulfills in and exclusions criterias. Selection of the target hand will adhere to the following, with advancement to next step if unable to choose target hand based on the given criteria. 1. The hand with most overall pain, assessed by VAS finger joint pain. 2. The hand with most overall reduced function, assessed by function subscale. 3. The hand with most overall stiffness, assessed by stiffness subscale. 4. The hand with most swollen joints, assessed by physician joint count. 5. The hand with most tender joints, assessed by physician joint count. 6. The hand with highest summed radiographic score, assessed by radiographic scoring of conventional X-ray. 7. If unable to select target hand based on the above a target hand will be randomly assigned